The team used an AI method known as equation discovery to develop a model to simulate the interactions between small eddies—circular, vortex-like currents—and large-scale ones. These interactions are ...

In mathematics, proofs can be written down and shared. In cryptography, when people are trying to avoid revealing their ...

AI systems are beginning to produce proof ideas that experts take seriously, even when final acceptance is still pending.

Print Join the Discussion View in the ACM Digital Library The mathematical reasoning performed by LLMs is fundamentally different from the rule-based symbolic methods in traditional formal reasoning.

Nvidia founder and CEO Jensen Huang speaks about the NVIDIA Rubin AI super computing platform during a Nvidia news conference ...

A recent episode of HBO's "The Pitt" tackles generative AI in medicine, getting some things right, some wrong and leaving out ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The original version of this story appeared in Quanta Magazine. If you want to solve a tricky problem, it often helps to get organized. You might, for example, break the problem into pieces and tackle ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...